CLINICAL TRIAL / NCT03992755
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
- Interventional
- Active
- NCT03992755
Contact Information
A Global, Open-Label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
One of the greatest impediments to patient treatment satisfaction with current inhaled
treprostinil therapy is inconvenience. Currently, PAH patients using inhaled treprostinil may
require more than 36 breaths per day using a nebulizer requiring daily set up and cleaning.
The use of a discrete, hand-held dry powder inhaler to deliver treprostinil to the lungs
could represent a major improvement in convenience and patient satisfaction, thereby
improving the quality of life for PAH patients. Liquidia is pursuing approval of LIQ861, an
inhalation dry powder formulation of treprostinil that is produced using Liquidia's PRINT®
Technology (Particle Replication in Nonwetting Templates), as an alternative to current
inhaled treprostinil therapy for the treatment of patients with PAH (WHO Group 1).
Gender
All
Age Group
18 Years and up
Accepting Healthy Volunteers
No
Inclusion Criteria:
1. Evidence of a personally signed and dated informed consent document exists indicating
that the patient has been informed of all pertinent aspects of the study prior to
initiation of any study-related procedures.
2. Patient is willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.
3. Patient has fulfilled all entry criteria at the time of enrollment in original study
with LIQ861.
4. Patient has completed the protocol defined end of study procedures or met a
protocol-defined and adjudicated endpoint in the original LIQ861 study in which they
were enrolled.
5. Patient, whether male or female, agrees to use a medically acceptable method of
contraception throughout the entire study period from informed consent through the
termination visit, if the possibility of conception exists. Eligible male and female
patients must also agree not to participate in a conception process (e.g., actively
attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization)
during the study and for 30 days after the last dose of LIQ861.
Exclusion Criteria:
1. Patient prematurely discontinued LIQ861 due to a drug-related AE/SAE or tolerability
issue in the original LIQ861 study in which they were enrolled, or patient did not
complete protocol defined study procedures at an end of study visit (not Early
Termination visit) in their original LIQ861 study.
2. Patient withdrew consent during participation in another LIQ861 study.
3. Patient is a female who wishes to become pregnant or who has a positive pregnancy test
on Day 1 (LTI-302 Study Initiation Visit).
4. Patient has undergone lung or heart/lung transplant or the initiation of parenteral
(intravenous [IV] infusion or subcutaneous injection) therapy with a prostacyclin
during the time since participation in their original LIQ861 study.
5. Any reason exists that, in the opinion of the Investigator or Medical Monitor,
precludes the patient from participating in the study, e.g., any previous or
intercurrent medical condition that may increase the risk associated with study
participation or that would confound study analysis or impair study participation or
cooperation.